health economics and outcomes research

Research in Review

Health Insurance Status a Significant Influencer of Cancer Outcomes

08/08/2016

JCP Editors

Two studies published online in the journal Cancer have shown that patients’ health insurance status may impact outcomes following cancer diagnosis. Using population-based data from the Surveillance, Epidemiology,...

Two...

08/08/2016

Journal of Clinical Pathways

Research in Review

Cisplatin and Paclitaxel Most Cost-Effective Chemotherapy Combination for Cervical Cancer

06/28/2016

JCP Editors

Cisplatin and paclitaxel may be the most cost-effective chemotherapy combination for women with advanced, persistent, or recurrent cervical cancer, according to research published in Dovepress. In the study,...

...

06/28/2016

Journal of Clinical Pathways

Research in Review

FDA Approval Process Flawed for Cancer Drugs

05/30/2016

JCP Editors

A study published in Mayo Clinic Proceedings has called into question how the Food and Drug Administration (FDA) uses surrogate endpoints in approvals for certain cancer medications. Surrogate endpoints are measures...

A...

05/30/2016

Journal of Clinical Pathways

Research in Review

Nutritional Status an Indicator of Survival in Patients With Esophageal Cancer

05/25/2016

JCP Editors

Nutritional status may be a prominent indicator of survival in elderly patients with esophageal cancer, claims a recently published study. Esophageal cancer is one of the leading causes of cancer-related death...

...

05/25/2016

Journal of Clinical Pathways

Research in Review

Costs of Adverse Events Quantified for Breast Cancer Patients

05/24/2016

JCP Editors

Adverse events (AEs) may be a driver of high health care costs in patients with metastatic breast cancer treated with systemic therapy, according to a new study. AEs are a serious concern for patients and providers,...

...

05/24/2016

Journal of Clinical Pathways

Research in Review

Value for US Cancer Drug Spending Lags Behind Other Nations

05/03/2016

JCP Editors

A study of international cancer care costs has revealed that the value of US cancer drug spending has not kept pace with that of other nations in terms of health gains per dollar spent. Sebastian Salas-Vega, MSc,...

A...

05/03/2016

Journal of Clinical Pathways

Radiation Therapy Better for Testicular Cancer Than Chemotherapy

05/02/2016

JCP Editors

Radiation therapy may be superior to chemotherapy for patients with stage 2a-b testicular cancer, according to results presented at European Society for Therapeutic Radiology and Oncology (ESTRO) 35 (April 29-May 3,...

...

05/02/2016

Journal of Clinical Pathways

Research in Review

Adding Chemotherapy to Radiation Therapy Improves Long-Term Outcomes for Patients With Low-Grade Brain Tumors

04/08/2016

JCP Editors

The combination of chemotherapy and radiation therapy may improve progression-free survival (PFS) and overall survival in patients with grade 2 glioma, according to a recent study. Glioma is a form of brain cancer...

The...

04/08/2016

Journal of Clinical Pathways

Research in Review

Co-Testing a More Cost-Effective Screening Strategy for Cervical Cancer Than HPV Primary

04/01/2016

JCP Editors

A model developed using data from health care databases and published literature has found that Pap plus human papillomavirus (HPV) mRNA testing that includes genotying for HPV 16 and 18 may be a more effective...

A...

04/01/2016

Journal of Clinical Pathways

Research in Review

Gene-Expression Test Cost-Effective for Determining Unknown Tumor Origins

03/31/2016

JCP Editors

The 2000-gene-expression profiling (GEP) test may be a more cost-effective option than current strategies for identifying tumor origin in patients with cancer of unknown primary (CUP), a recent study...

The...

03/31/2016

Journal of Clinical Pathways